L
Liangxing Wu
Researcher at Wilmington University
Publications - 5
Citations - 96
Liangxing Wu is an academic researcher from Wilmington University. The author has contributed to research in topics: Fibroblast growth factor receptor & Ligand (biochemistry). The author has an hindex of 2, co-authored 5 publications receiving 34 citations.
Papers
More filters
Journal ArticleDOI
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.
Phillip C.C. Liu,Holly Koblish,Liangxing Wu,Kevin Bowman,Sharon Diamond,Darlise DiMatteo,Yue Zhang,Michael Hansbury,Mark Rupar,Xiaoming Wen,Paul Collier,Patricia Feldman,Ronald M. Klabe,Krista A. Burke,Maxim Soloviev,Christine Gardiner,Xin He,Alla Volgina,Maryanne B. Covington,Bruce Ruggeri,Richard Wynn,Timothy Burn,Peggy Scherle,Swamy Yeleswaram,Wenqing Yao,Reid Huber,Gregory Hollis +26 more
TL;DR: The preclinical data presented for INCB054828, together with preliminary clinical observations, support continued investigation in patients with FGFR alterations, such as fusions and activating mutations, and suggest target inhibition is achievable by INCB 19054828 in vivo with low oral doses.
Proceedings ArticleDOI
Abstract 4483: Novel small-molecule antagonists of the PD-1/PD-L1 axis that mediate cell surface PD-L1 dimerization and internalization
Phillip C.C. Liu,Richard Wynn,Liangxing Wu,Alla Volgina,Nina I. Zolotarjova,Luping Lin,Pramod Thekkat,Alex Margulis,Ronald M. Klabe,Wenqing Yao,Kaijiong Xiao,Jingwei Li,Xin He,Mark Rupar,Hong Chang,Paul Waeltz,Yanlong Li,Peggy Scherle,Reid Huber,Gregory Hollis +19 more
TL;DR: The identification and characterization of novel small molecule antagonists of thePD-(L)1 axis that function by inducing dimerization and subsequent internalization of the PD-L1 protein, effectively depleting the ligand from the cell membrane and preventing PD-1 activation on T cells are described.
Proceedings ArticleDOI
Abstract 2100: Selective inhibition of FGFR4 by INCB062079 is efficacious in models of FGF19- and FGFR4-dependent cancers
Phillip C.C. Liu,Liang Lu,Kevin Bowman,Matthew C. Stubbs,Liangxing Wu,Darlise DiMatteo,Sindy Condon,Ronald M. Klabe,Ding-Quan Qian,Xiaoming Wen,Paul Collier,Karen Gallagher,Michael Hansbury,Xin He,Bruce Ruggeri,Yan-ou Yang,Maryanne B. Covington,Timothy Burn,Sharon Diamond-Fosbenner,Richard Wynn,Reid Huber,Wenqing Yao,Swamy Yeleswaram,Peggy Scherle,Gregory Hollis +24 more
TL;DR: Preclinical studies demonstrate that INCB062079 potently and selectively inhibits models of FGF19-FGFR4-dependent cancers in vitro and in vivo, supporting clinical evaluation in patients harboring oncogenic FGFR4 activation.
Proceedings ArticleDOI
Abstract 531: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer
Phillip C.C. Liu,Brian D. Lehmann,Bruce Ruggeri,Darlise DiMatteo,Johanna M. Schafer,Jin Lu,Sang Hyun Lee,Luping Lin,Timothy Burn,Melody Diamond,Alla Volgina,Liangxing Wu,Gregory Hollis,Reid Huber,Jennifer A. Pietenpol,Peggy Scherle +15 more
TL;DR: Activity of the selective FGFR 1, 2 and 3 inhibitor INCB054828 in genetically-defined models of triple-negative breast cancer was associated with suppression of growth promoting pathways including Ras-MAPK and inhibition of cell viability.
Patent
Dérivés de benzooxazole en tant qu'mmunomodulateurs
Liangxing Wu,Jingwei Li,Chao Qi,Fenglei Zhang,Zhenwu Li,Wenyu Zhu,Zhiyong Yu,Kaijiong Xiao,Liang Lu,Song Mei,Ding-Quan Qian,Chunhong He,Yingda Ye,Meizhong Xu,Wenqing Yao +14 more
TL;DR: Invention concerne des composes de formule (I), des methodes d'utilisation de ces composes comme immunomodulateurs, and des compositions pharmaceutiques comprenant de tels composes as discussed by the authors.